☆ 4.7 Meeting Abstract

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) plus capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

JOURNAL OF CLINICAL ONCOLOGY (2017)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 35, Issue 4, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2017.35.4_suppl.343

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) plus capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) plus capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper